Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company pioneering novel antibiotics for resistant Gram-positive infections. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's scientific advancements and regulatory progress.
Access timely reports on clinical trial developments, including Phase 3 preparations for ibezapolstat targeting C. difficile infections. Stay informed about patent grants, research collaborations, and financial disclosures that demonstrate ACXP's commitment to addressing antimicrobial resistance through targeted DNA polymerase IIIC inhibition technology.
Our curated collection features press releases detailing milestone achievements, peer-reviewed study publications, and strategic partnership announcements. All content is verified for accuracy and relevance to support informed decision-making in the evolving antibiotic development landscape.
Bookmark this page for direct access to Acurx's latest progress in creating narrow-spectrum therapies that combat priority pathogens while preserving microbiome balance – a critical differentiator in modern infectious disease treatment.
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the Indian Patent Office in March 2025 for DNA Polymerase IIIC Inhibitors, including compositions-of-matter. This adds to their existing portfolio of three U.S. patents, one Israeli patent, and one Japanese patent, all covering the ACX-375C program.
The company's lead DNA pol IIIC inhibitor is Phase 3-ready for oral treatment of C. difficile Infection. Their second-generation compounds are being developed for both oral and parenteral use to treat infections caused by gram-positive bacteria, including:
- Staphylococcus aureus (including MRSA)
- VRE and DRSP
- B. anthracis (anthrax), a Bioterrorism Category A Threat-Level pathogen
Acurx Pharmaceuticals (NASDAQ: ACXP) has reported its Q4 and full-year 2024 results. Key highlights include positive Phase 2b clinical trial results for ibezapolstat, showing a 96% clinical cure rate across combined Phase 2 trials, with 100% sustained cure rate through one month post-treatment, compared to 86% for vancomycin.
The company secured positive regulatory guidance from EMA for ibezapolstat's Phase 3 program, aligning with FDA requirements. Financial results show cash position of $3.7 million as of December 31, 2024, down from $7.5 million year-over-year. The company raised $6.6 million through ATM financing in 2024.
Q4 2024 showed reduced losses with net loss of $2.8 million ($0.16 per share) compared to $5.1 million ($0.37 per share) in Q4 2023. Full-year 2024 net loss was $14.1 million ($0.87 per share) versus $14.6 million ($1.15 per share) in 2023.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced the closing of a $1.1 million registered direct offering, consisting of 2,745,000 shares of common stock priced at $0.40 per share. The late-stage biopharmaceutical company, focused on developing new antibiotics for difficult-to-treat bacterial infections, also issued unregistered warrants in a concurrent private placement.
The warrants allow for the purchase of up to 8,235,000 shares at an exercise price of $0.40 per share, exercisable upon stockholder approval and expiring 24 months thereafter. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a $1.1 million registered direct offering of 2,745,000 shares of common stock at $0.40 per share. The late-stage biopharmaceutical company, focused on developing new antibiotics for difficult-to-treat bacterial infections, will also issue unregistered warrants for up to 8,235,000 shares in a concurrent private placement.
The warrants will have an exercise price of $0.40 per share and will expire 24 months after stockholder approval. The offering, expected to close around March 10, 2025, is being managed by H.C. Wainwright & Co. as the exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The common stock shares are being offered through a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Acurx Pharmaceuticals (NASDAQ: ACXP) has published groundbreaking research comparing the gut microbiome effects of its lead antibiotic candidate ibezapolstat (IBZ) with other antibiotics used to treat C. difficile Infection (CDI).
The study, published in the Journal of Antimicrobial Agents and Chemotherapeutics, revealed that IBZ caused less disruption to gut microbiome diversity compared to vancomycin (VAN) and metronidazole (MET). The research showed IBZ increased the relative abundance of Bacteroidota and Actinomycetota phyla, with the latter including beneficial bacteria like Bifidobacteria.
Notable differences were observed between IBZ and fidaxomicin (FDX), potentially differentiating these two anti-CDI antibiotics in future studies. IBZ is preparing to advance to international Phase 3 clinical trials for CDI treatment and has received FDA QIDP, Fast-Track Designation, and EMA SME designation.
Acurx Pharmaceuticals (NASDAQ: ACXP), a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult-to-treat bacterial infections, has scheduled its fourth quarter and full year 2024 financial results conference call for March 18, 2025, at 8:00 am ET. The announcement will take place before U.S. market opening, with President and CEO David P. Luci and CFO Robert G. Shawah hosting the call to discuss financial performance and provide a business update.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced positive results from an in-silico study of ibezapolstat (IBZ), its lead antibiotic candidate for C. difficile Infection (CDI) treatment. The study, published in the Journal of Antimicrobial Agents and Chemotherapeutics, explains IBZ's selective antimicrobial activity.
The research revealed that IBZ's bactericidal interaction with its target DNA pol IIIC is conserved across most Bacillota phylum, including C. difficile, while beneficial gut bacteria remain naturally resistant. This mechanism explains the narrower spectrum of activity observed in human trials, where IBZ allowed the regrowth of beneficial microbiota.
The study, funded by the National Institute of Allergy and Infectious Diseases, demonstrates IBZ's advantage over vancomycin, which kills beneficial microbes and leads to higher C. difficile recurrence rates. IBZ is preparing to advance to international Phase 3 clinical trials and has received FDA QIDP, Fast-Track, and EMA SME designations.
Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the Japanese Patent Office in January 2025 for DNA Polymerase IIIC Inhibitors, covering compositions-of-matter, surface coatings, and pharmaceutical compositions for treating Gram-positive bacterial infections. This adds to their existing portfolio of three U.S. patents, one Israeli patent, and additional pending applications.
The company has received positive regulatory guidance from the EMA for its Phase 3-ready ibezapolstat program, designed to treat and prevent recurrence of C. difficile Infection. The EMA's Scientific Advice Procedure confirmed that Acurx's clinical, non-clinical, and CMC package supports advancement to Phase 3 trials and potential MAA submission in Europe.
The planned Phase 3 program consists of two international trials comparing ibezapolstat to vancomycin, with 450 subjects in the Modified Intent-To-Treat population for the initial trial. The study will evaluate both Clinical Cure of CDI and potential reduction in recurrence rates.
Acurx Pharmaceuticals (NASDAQ: ACXP) has completed its previously announced registered direct offering, raising $2.5 million through the sale of 2,463,058 common stock shares at $1.015 per share, priced at-the-market under Nasdaq rules. The company also issued unregistered warrants in a concurrent private placement to purchase up to 2,463,058 shares at an exercise price of $0.90 per share, exercisable immediately and expiring in five years.
H.C. Wainwright & Co. served as the exclusive placement agent. The net proceeds, after deducting placement agent fees and offering expenses, will be used for working capital and general corporate purposes. The common stock shares were offered through a shelf registration statement, while the warrants were issued through a private placement under Section 4(a)(2) of the Securities Act.
Acurx Pharmaceuticals (NASDAQ: ACXP) has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,463,058 shares of common stock at $1.015 per share. Additionally, in a concurrent private placement, ACXP will issue unregistered warrants to purchase up to 2,463,058 shares with an exercise price of $0.90 per share, exercisable upon issuance and expiring in five years.
The offering, expected to close around January 7, 2025, is being conducted with H.C. Wainwright & Co. as the exclusive placement agent. The net proceeds will be used for working capital and general corporate purposes. The common stock shares are being offered through a shelf registration statement, while the warrants are being issued in a private placement under Section 4(a)(2) of the Securities Act.
